IP Library › Granted Patent US 12,391,726
Granted Patent B2
US 12,391,726 · App. 19/060,293 · Granted Aug 19, 2025

Ursolic acid morpholine salt

Inventor: John J. Talley (St. Louis, MO)
Assignee: EMMYON, INC.
C07J63/008A23L29/03A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,726
App. No.
19/060,293
Granted
Aug 19, 2025
Kind
B2
Abstract

The invention provides ursolic acid morpholine salt. Compositions containing the salt are also provided.

Claims (20)

1. An ursolic acid salt, wherein the salt is ursolic acid morpholine salt of formula

2. A composition comprising the ursolic acid morpholine salt according to claim 1 , and a further agent.

3. The composition according to claim 2 , comprising 25 to 1,500 mg of the salt.

4. The composition according to claim 2 , comprising 50 to 1,000 mg of the salt.

5. The composition according to claim 2 , wherein the further agent comprises a physiologically acceptable carrier.

6. The composition according to claim 5 , comprising 25 to 1,500 mg of the salt.

7. The composition according to claim 5 , comprising 50 to 1,000 mg of the salt.

8. The composition according to claim 2 , wherein the composition is a nutraceutical composition.

9. The composition according to claim 2 , wherein the composition is a pharmaceutical composition.

10. The pharmaceutical composition according to claim 9 , comprising 25 to 1,500 mg of the ursolic acid morpholine salt.

11. The pharmaceutical composition according to claim 9 , comprising 50 to 1,000 mg of the ursolic acid morpholine salt.

12. The pharmaceutical composition according to claim 9 , in a dosage form that provides 0.001 to 500 mg of the ursolic acid morpholine salt per kg of subject body weight.

13. The pharmaceutical composition according to claim 9 , in a dosage form that provides 0.01 to 100 mg of the ursolic acid morpholine salt per kg of subject body weight.

14. The composition according to claim 2 , wherein the composition is a food composition.

15. The food composition according to claim 14 , comprising 25 to 1,500 mg of the ursolic acid morpholine salt.

16. The food composition according to claim 14 , comprising 50 to 1,000 mg of the ursolic acid morpholine salt.

17. The composition according to claim 2 , wherein the composition is a dietary supplement.

18. The dietary supplement according to claim 17 , comprising 25 to 1,500 mg of the ursolic acid morpholine salt.

19. The dietary supplement composition according to claim 17 , comprising 50 to 1,000 mg of the ursolic acid morpholine salt.

20. The composition according to claim 2 , wherein the composition is a dietary supplement in a dosage form that provides 0.01 to 100 mg of the ursolic acid morpholine salt per kg of subject body weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2025
From: TALLEY, JOHN J.
To: EMMYON, INC.
Reel/Frame 070309/0216 →
Continuity (6)
Continuation 18910781 · Oct 9, 2024
Division 16811730 · Mar 6, 2020
Continuation In Part PCTUS2018049742 · Sep 6, 2018
Provisional Application 62649938 · Mar 29, 2018
Provisional Application 62558004 · Sep 13, 2017
Related Publication 20250188114A1 · Jun 12, 2025
References Cited (59)
US 9295664B2 · Adams et al. · 2016 [cited by applicant]
US 9856204B2 · Adams et al. · 2018 [cited by applicant]
US 10137136B2 · Adams et al. · 2018 [cited by applicant]
US 20030153538A1 · Kuno et al. · 2003 [cited by applicant]
US 20160304553A1 · Baharaff et al. · 2016 [cited by applicant]
US 20170056414A1 · Slaga et al. · 2017 [cited by applicant]
US 20200207802A1 · Talley · 2020 [cited by applicant]
US 20250034203A1 · Talley · 2025 [cited by applicant]
CN 1450900A · 2003 [cited by applicant]
CN 101891795A · 2010 [cited by applicant]
CN 102241723A · 2011 [cited by applicant]
CN 102516351A · 2012 [cited by applicant]
CN 103037692A · 2013 [cited by applicant]
CN 104688745A · 2015 [cited by applicant]
CN 106822153A · 2017 [cited by applicant]
EP 1321145A1 · 2003 [cited by applicant]
EP 1566170A1 · 2005 [cited by applicant]
JP H1129467A · 1999 [cited by applicant]
JP 2003313774A · 2003 [cited by applicant]
JP 2014507422A · 2014 [cited by applicant]
JP 2015510515A · 2015 [cited by applicant]
JP 2015516422A · 2015 [cited by applicant]
KR 20120028043A · 2012 [cited by applicant]
WO 2002043736A1 · 2002 [cited by applicant]
WO 2002078468A1 · 2002 [cited by applicant]
WO 2011115069A1 · 2011 [cited by applicant]
WO 2011146768A1 · 2011 [cited by applicant]
WO WO2011146768 · 2011 [cited by examiner]
WO 2012170546A1 · 2012 [cited by applicant]
WO 2019055280A1 · 2019 [cited by applicant]
Aronson (Brit J Clin Pharmacol 83:8-19, 2017) (Year: 2017). [cited by examiner]
Wozniak, L., Skapska, S., and Marszalek, K. (2015) Ursolic Acid—A Pentacyclic Triterpenoid with a Wide Spectrum of Pharmacological Activities. [cited by applicant]
Liu, J. (2005) Oleanolic acid and ursolic acid: research perspectives. [cited by applicant]
Sultana, N. (2011) Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. [cited by applicant]
Liu, J. (1995) Pharmacology of oleanolic acid and ursolic acid. [cited by applicant]
Shanmugam, M. K., Dai, X., Kumar, A. P., Tan, B. K., Sethi, G., and Bishayee, A. (2013) Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. [cited by applicant]
Kashyap, D., Tuli, H. S., and Sharma, A. K. (2016) Ursolic acid (UA): A metabolite with promising therapeutic potential. [cited by applicant]
Lopez-Hortas, L., Perez-Larran, P., Gonzalez-Munoz, M. J., Falque, E., and Dominguez, H. (2018) Recent developments on the extraction and application of ursolic acid. A review. [cited by applicant]
Pironi, A. M., de Araujo, P. R., Fernandes, M. A., Salgado, H. R. N., and Chorilli, M. (2018) Characteristics, Biological Properties and Analytical Methods of Ursolic Acid: A Review. [cited by applicant]
Cargnin, S. T., and Gnoatto, S. B. (2017) Ursolic acid from apple pomace and traditional plants: A valuable triterpenoid with functional properties. [cited by applicant]
Lee, S. U., Park, S. J., Kwak, H. B., Oh, J., Min, Y. K., and Kim, S. H. (2008) Anabolic activity of ursolic acid in bone: Stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. [cited by applicant]
Lu, J., Zheng, Y. L., Wu, D. M., Luo, L., Sun, D. X., and Shan, Q. (2007) Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. [cited by applicant]
Wang, X. T., Gong, Y., Zhou, B., Yang, J. J., Cheng, Y., Zhao, J. G., and Qi, M. Y. (2018) Ursolic acid ameliorates oxidative stress, inflammation and fibrosis in diabetic cardiomyopathy rats. [cited by applicant]
Zhou, Y., Li, J. S., Zhang, X., Wu, Y. J., Huang, K., and Zheng, L. (2010) Ursolic acid inhibits early lesions of diabetic nephropathy. [cited by applicant]
Ling, C., Jinping, L., Xia, L., and Renyong, Y. (2013) Ursolic Acid provides kidney protection in diabetic rats. [cited by applicant]
Ding, H., Wang, H., Zhu, L., and Wei, W. (2017) Ursolic Acid Ameliorates Early Brain Injury After Experimental Traumatic Brain Injury in Mice by Activating the Nrf2 Pathway. [cited by applicant]
Ma, J. Q., Ding, J., Zhang, L., and Liu, C. M. (2015) Protective effects of ursolic acid in an experimental model of liver fibrosis through Nrf2/ARE pathway. [cited by applicant]
Zhang, T., Su, J., Wang, K., Zhu, T., and Li, X. (2014) Ursolic acid reduces oxidative stress to alleviate early brain injury following experimental subarachnoid hemorrhage. [cited by applicant]
Hwang, T. L., Shen, H. I., Liu, F. C., Tsai, H. I., Wu, Y. C., Chang, F. R., and Yu, H. P. (2014) Ursolic acid inhibits superoxide production in activated neutrophils and attenuates trauma-hemorrhage shock-induced organ… [cited by applicant]
Martinez-Abundis, E., Mendez-Del Villar, M., Perez-Rubio, K. G., Zuniga, L. Y., Cortez-Navarrete, M., Ramirez-Rodriguez, A., and Gonzalez-Ortiz, M. (2016) Novel nutraceutic therapies for the treatment of metabolic syndr… [cited by applicant]
Somova, L. O., Nadar, A., Rammanan, P., and Shode, F. O. (2003) Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. [cited by applicant]
Somova, L. I., Shode, F. O., Ramnanan, P., and Nadar, A. (2003) Antihypertensive, antiatherosclerotic and antioxidant activity of triterpenoids isolated from [cited by applicant]
Dyle et al., “Systems-based Discovery of Tomatidine as a Natural Small Molecule Inhibitor of Skeletal Muscle Atrophy,” The Journal of Biological Chemistry, vol. 289, No. 21, May 23, 2014, pp. 14913-14924. [cited by applicant]
Kunkel et al., “mRNA Expression Signatures of Human Skeletal Muscle Atrophy Identify a Natural Compound that Increases Muscle Mass,” Cell Metabolism 13, Jun. 8, 2011, pp. 627-638. [cited by applicant]
Kunkel et al., “Ursolic Acid Increases Skeletal Muscle and Brown Fat and Decreases Diet-Induced Obesity, glucose Intolerance and Fatty Liver Disease,” PLOS One, vol. 7, Issue 6, Jun. 2012 pp. 1-8. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority from PCT/US2018/049742, mailed Jan. 22, 2019. [cited by applicant]
Qiang Lee et al., A New Brochure of Effective Components in Traditional Chinese Medicine, Peking Union Medical College Press. Jan. 31, 2008. pp. 651-652, Abstract Only. [cited by applicant]
Qingguo Meng et al., “Research Progress in Synthesis and Activity of Ursolic Acid Derivatives”. Journal of Jining Medical College, vol. 40, No. 40: Aug. 20, 2017. pp. 246-247, Abstract Only. [cited by applicant]
Fengjuan Xia et al., “Research progress of structure modification technology in domestic patents related to ursolic acid derivatives”. China Medical Herald, vol. 10, No. 27, Sep. 25, 2013. pp. 33-36, Abstract Only. [cited by applicant]